Meeting
2021 ASCO Annual Meeting
Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors.
Authors
Jason J. Luke
UPMC Hillman Cancer Center, Pittsburgh, PA
Jason J. Luke , Anthony J. Olszanski , Igor Puzanov , Dan Lu , Adrian Hackett , Stella Martomo , Jeegar Patel , Olivier Schueller , Alessandro Mora , Miranda Schlitt , Linghui Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Monotherapy
Clinical Trial Registration Number
NCT04242147
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2568)
DOI
10.1200/JCO.2021.39.15_suppl.2568
Abstract #
2568
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.
First Author: Gerald Steven Falchook
Poster
2022 ASCO Annual Meeting
First-in-human dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim data.
First Author: Eugene R Ahn
Poster
2017 ASCO Annual Meeting
Effect of PD1/PD-L1 checkpoint blockade on efficacy of anti-GD2 antibody ch14.18/CHO in neuroblastoma.
First Author: Holger N. Lode
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang